The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells

相似書籍

• Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells
  由: Valdez, Benigno C., et al.
  出版: (2020)
• Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines
  由: Valdez, Benigno C., et al.
  出版: (2011)
• Cladribine, gemcitabine, busulfan and SAHA combination as a potential pre-transplant conditioning regimen for lymphomas: a preclinical study
  由: Ji, Jie, et al.
  出版: (2016)
• Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
  由: Nieto, Yago, et al.
  出版: (2015)
• Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells
  由: Valdez, Benigno C., et al.
  出版: (2017)